Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients

OBJECTIVES: Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is site‐limited. Liquid biopsy represents a minimal...

Descripción completa

Detalles Bibliográficos
Autores principales: Vrabel, David, Sedlarikova, Lenka, Besse, Lenka, Rihova, Lucie, Bezdekova, Renata, Almasi, Martina, Kubaczkova, Veronika, Brožová, Lucie, Jarkovsky, Jiri, Plonkova, Hana, Jelinek, Tomas, Sandecka, Viera, Stork, Martin, Pour, Ludek, Sevcikova, Sabina, Hajek, Roman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065130/
https://www.ncbi.nlm.nih.gov/pubmed/31763708
http://dx.doi.org/10.1111/ejh.13358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065130/
https://www.ncbi.nlm.nih.gov/pubmed/31763708
http://dx.doi.org/10.1111/ejh.13358

Ejemplares similares